Brainomix presents robust validation of its FDA-cleared e-Lung technology
OXFORD, UK, and CHICAGO, USA May 16th 2025 – Brainomix, a company pioneering AI-powered imaging solutions in lung fibrosis and stroke, will be presenting new evidence next week at the American Thoracic Society (ATS) Conference in San Francisco validating its Brainomix 360 e-Lung technology to identify progressive pulmonary fibrosis accurately and sensitively.
Through a research collaboration with Boehringer Ingelheim, the global leader in pulmonary fibrosis therapies, Brainomix were granted privileged access to the landmark INBUILD clinical trial dataset to run the first quantitative CT analysis. The results firmly validate e-Lung as a reliable tool for identifying progressive pulmonary fibrosis accurately and sensitively, while also demonstrating its prognostic accuracy in identifying patients at risk of progressive pulmonary fibrosis.
Dr Susanne Stowasser, Associate Head of Medicine Therapeutic Area Inflammation at Boehringer Ingelheim said:
As part of our purpose of Transforming Lives for Generations at Boehringer, we seek collaborations to create value for patients. The imaging data presented at ATS from our INBUILD clinical trial in patients with progressive pulmonary fibrosis are part of a collaboration with Brainomix and others to advance the development of imaging biomarkers for better prognostication and prediction of response to therapy and ultimately patient care.
The studies will be presented on May 21st at ATS by Prof Anand Devaraj and Dr Peter George, both based at the Royal Brompton Hospital in London.
Brainomix 360 e-Lung is an imaging software that automatically quantifies CT biomarkers in patients with interstitial lung disease (ILD), powered by novel, proprietary technology. With a recent expansion of its FDA clearance, the next generation e-Lung technology represents a significant step forward for the care of patients with ILD, with improved AI and machine learning (ML) algorithms, and a longitudinal assessment functionality that enables clinicians to more easily track results across multiple scan timepoints.
A subset of ILDs, pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Untreated, patients can have a lifespan as short as three to five years from diagnosis, and yet despite this, often wait up to two years to be diagnosed. The key to the best outcome and survival for patients with pulmonary fibrosis is early initiation of treatment.
However, identifying patients eligible for treatment based on imaging can be challenging, even for experts.
Dr Peter George, Consultant Pulmonologist at the Royal Brompton NHS Trust UK and Brainomix Medical Director said:
e-Lung is a powerful tool, more sensitive to progression than visual analysis and more accurate than lung function change. This ability to accurately identify serial change can help physicians to make better treatment decisions at an earlier time point. The prognostic capabilities also allow physicians to prioritize at-risk patients for earlier follow-up, and to escalate their care in a more timely manner.
The Brainomix and Boehringer strategic partnership announced in 2024 is a collaborative programme of activity with the aim of improving the care of patients with progressive pulmonary fibrosis. Early collaborations with leading US pulmonary sites and registries have already provided real-world validation of e-Lung to improve the identification of patients with progressive pulmonary fibrosis.